$0.30
3.14% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Stock price

$0.31
-0.07 19.57% 1M
-0.09 23.43% 6M
-0.22 42.17% YTD
-1.85 85.82% 1Y
-12.65 97.64% 3Y
-33.73 99.10% 5Y
-30.47 99.01% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.01 2.03%
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

Key metrics

Market capitalization $30.90m
Enterprise Value $112.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.72
P/S ratio (TTM) P/S ratio 0.20
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 5.59%
Revenue (TTM) Revenue $156.01m
EBIT (operating result TTM) EBIT $-46.44m
Free Cash Flow (TTM) Free Cash Flow $-138.27m
Cash position $50.48m
EPS (TTM) EPS $-0.48
P/E forward negative
P/S forward 5.15
EV/Sales forward 18.77
Short interest 5.80%
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

Buy
50%
Hold
50%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
156 156
6% 6%
100%
- Direct Costs 31 31
63% 63%
20%
125 125
3% 3%
80%
- Selling and Administrative Expenses 68 68
35% 35%
44%
- Research and Development Expense 101 101
64% 64%
65%
-44 -44
83% 83%
-28%
- Depreciation and Amortization 2.69 2.69
73% 73%
2%
EBIT (Operating Income) EBIT -46 -46
83% 83%
-30%
Net Profit -48 -48
83% 83%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
GlobeNewsWire
about 21 hours ago
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.
Neutral
Seeking Alpha
17 days ago
FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call Participants Andy Sieh - William Blair Matthew Keller - H.C. Wainwright Operator Hello everyone, and welcome to the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
17 days ago
SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2024 and provided an update on the company's recent developments.
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 225
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today